Register Login

SENTI BIOSCIENCES, INC. (SNTI)

SymbolSNTI
NameSENTI BIOSCIENCES, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address2 CORPORATE DRIVE,FIRST FLOOR, SOUTH SAN FRANCISCO, California, 94080, United States
Telephone+1 650 239-2030
Fax—
Email—
Websitehttps://www.sentibio.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001854270
Description

Senti Biosciences Inc is engaged in creating new generation smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.

Additional info from NASDAQ:
Senti Biosciences Inc is engaged in creating new generation smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.

2026-07-16 14:56

New Form SCHEDULE 13D/A - Senti Biosciences Holdings, Inc. <b>Filed:</b> 2026-07-16 <b>AccNo:</b> 0000902664-26-003126 <b>Size:</b> 13 KB

Read more
2026-07-16 07:05

New Form S-3/A - Senti Biosciences Holdings, Inc. <b>Filed:</b> 2026-07-16 <b>AccNo:</b> 0001193125-26-305347 <b>Size:</b> 363 KB

Read more
2026-07-15 11:30

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

Read more
2026-05-26 20:02

(99% Neutral) SENTI BIOSCIENCES, INC. (SNTI) Announces Business Combination

Read more
2026-05-14 12:48

(10% Negative) SENTI BIOSCIENCES, INC. (SNTI) Reports Q2 2026 Financial Results

Read more
2026-05-14 12:45

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

Read more
2026-05-14 12:40

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

Read more
2026-05-08 18:18

New Form 15-12G - Senti Biosciences, Inc. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001193125-26-215046 <b>Size:</b> 15 KB

Read more
2026-05-04 18:00

New Form SCHEDULE 13D/A - Senti Biosciences, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0000902664-26-002262 <b>Size:</b> 17 KB

Read more
2026-05-01 20:06

(99% Neutral) SENTI BIOSCIENCES, INC. (SNTI) Announces Business Combination

Read more